Today we are discussing the management of patients with chronic lymphocytic leukemia (CLL), including incorporating the newest approved therapies for CLL: duvelisib and venetoclax.
We are joined by Dr. Ian Flinn, a hematologist/oncologist and the director of the Blood Cancer Research Program at Sarah Cannon Research Institute in Tennessee. Dr. Flinn treats patients with CLL and has taken part in many clinical trials of agents in development for the disease.
Transcript...
Typo in regard to Obinituzumab---it is anti CD-20 (not 28). Always the editor...
I think he must mean the side effect of splitting nails is not as threatening as other side effects--it seems to be quite important from our posts.
CLL Society Webinar Nov. 17th Dr. Joe Fraietta "The Future of CAR-T Therapy: Can CAR-T CURE CLL?" Some CAR-T patients are 10 years CLL-free!ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.Dr. Kanti Rai on the Future of CLL TherapyYABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success
Reflections from Cardiff, news of CLL research and the changing trials landscape
